Jiangsu Hengrui Medicine
600276.SS
#488
Rank
$40.79 B
Marketcap
$6.40
Share price
0.65%
Change (1 day)
1.59%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

P/E ratio for Jiangsu Hengrui Medicine (600276.SS)

P/E ratio as of March 2024 (TTM): 69.8

According to Jiangsu Hengrui Medicine 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 69.8494. At the end of 2022 the company had a P/E ratio of 63.2.

P/E ratio history for Jiangsu Hengrui Medicine from 2002 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202263.2-11.56%
202171.4-24.03%
202094.028.9%
201972.952.01%
201848.0-21.33%
201761.048.79%
201641.0-7.41%
201544.319.44%
201437.1-11.38%
201341.821.07%
201234.5-8.5%
201137.8-38.53%
201061.425.24%
200949.04.11%
200847.1-21.52%
200760.032.91%
200645.294.71%
200523.2-10.59%
200425.914.56%
200322.6-30.19%
200232.4

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.